GlassScriptPhysician profile
Kirby Carlson
NPI 1942970348
$1,586.49
in general payments reported to CMS, 2019-2025
18 companies · $228 in 2025
The $228 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $259 · 2023: $676 · 2024: $423 · 2025: $228.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,327.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,327.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $622.17 | 2022-2025 | Repatha, Repatha |
| Merck Sharp & Dohme LLC | $174.02 | 2022-2025 | Verquvo, Winrevair |
| Novartis Pharmaceuticals Corporation | $134.70 | 2023-2025 | Leqvio |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $80.31 | 2022-2025 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $76.85 | 2022-2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $76.84 | 2023-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $67.84 | 2023-2025 | Camzyos, Eliquis |
| Bridgebio Pharma, INC. | $61.65 | 2025 | Attruby |
| Abiomed | $61.04 | 2023-2024 | Impella |
| Astrazeneca Pharmaceuticals LP | $47.17 | 2023-2024 | Brilinta, Wainua |
| Actelion Pharmaceuticals US, INC. | $43.96 | 2023-2025 | Uptravi, Opsumit |
| Kiniksa Pharmaceuticals International, Plc | $30.62 | 2024 | Arcalyst |
| Pfizer INC. | $28.53 | 2024-2025 | |
| United Therapeutics Corporation | $21.21 | 2025 | Tyvaso |
| Sanofi-Aventis U.S. LLC | $16.14 | 2024 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $15.98 | 2025 | |
| Medtronic, INC. | $14.75 | 2023 | Corevalve Evolut R |
| Kiniksa Pharmaceuticals, LTD. | $12.71 | 2023 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kirby Carlson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.